Search research articles
Contact Us
Filters
Showing results (41-50 of 72) with videos related to
Page
of 8
Sort By:
RNA (New York, N.Y.)
|
July 17, 2020
Determination of primary microRNA processing in clinical samples by targeted pri-miR-sequencing
Thomas Conrad, Evgenia Ntini, Benjamin Lang, et al.
Pharmaceutical Statistics
|
October 16, 2020
Assessing goodness-of-fit for evaluation of dose-proportionality
Martin J Wolfsegger, Alexander Bauer, Detlew Labes, et al.
British Journal of Clinical Pharmacology
|
February 24, 2017
Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies
Stephen Norris, Steven Ramael, Ippei Ikushima, et al.
The Journal of Allergy and Clinical Immunology
|
October 22, 2021
Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis
Patrick Baum, Sudha Visvanathan, Sandra Garcet, et al.
Cell Reports
|
September 16, 2014
Intrinsically disordered segments affect protein half-life in the cell and during evolution
Robin van der Lee, Benjamin Lang, Kai Kruse, et al.
Postgraduate Medicine
|
May 6, 2020
Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes
Ildiko Lingvay, Nadine Beetz, Regina Sennewald, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 6, 2014
Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir
John P Sabo, Jens Kort, Charles Ballow, et al.
The AAPS Journal
|
December 16, 2024
Rejoinder to the 'Letter to the Editor' on "Group-by-Treatment Interaction Effects in Comparative Bioavailability Studies"
Helmut Schütz, Divan A Burger, Erik Cobo, et al.
Lancet (London, England)
|
June 20, 2015
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial
Stephan Glund, Joachim Stangier, Michael Schmohl, et al.
Open Research Europe
|
September 11, 2024
Lockbox enrichment facilitates manipulative and cognitive activities for mice
Katharina Hohlbaum, Niek Andresen, Paul Mieske, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 72) with videos related to
Sort By:
Page
of 8
RNA (New York, N.Y.)
|
July 17, 2020
Determination of primary microRNA processing in clinical samples by targeted pri-miR-sequencing
Thomas Conrad, Evgenia Ntini, Benjamin Lang, et al.
Pharmaceutical Statistics
|
October 16, 2020
Assessing goodness-of-fit for evaluation of dose-proportionality
Martin J Wolfsegger, Alexander Bauer, Detlew Labes, et al.
British Journal of Clinical Pharmacology
|
February 24, 2017
Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies
Stephen Norris, Steven Ramael, Ippei Ikushima, et al.
The Journal of Allergy and Clinical Immunology
|
October 22, 2021
Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis
Patrick Baum, Sudha Visvanathan, Sandra Garcet, et al.
Cell Reports
|
September 16, 2014
Intrinsically disordered segments affect protein half-life in the cell and during evolution
Robin van der Lee, Benjamin Lang, Kai Kruse, et al.
Postgraduate Medicine
|
May 6, 2020
Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes
Ildiko Lingvay, Nadine Beetz, Regina Sennewald, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 6, 2014
Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir
John P Sabo, Jens Kort, Charles Ballow, et al.
The AAPS Journal
|
December 16, 2024
Rejoinder to the 'Letter to the Editor' on "Group-by-Treatment Interaction Effects in Comparative Bioavailability Studies"
Helmut Schütz, Divan A Burger, Erik Cobo, et al.
Lancet (London, England)
|
June 20, 2015
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial
Stephan Glund, Joachim Stangier, Michael Schmohl, et al.
Open Research Europe
|
September 11, 2024
Lockbox enrichment facilitates manipulative and cognitive activities for mice
Katharina Hohlbaum, Niek Andresen, Paul Mieske, et al.
Page
of 8